Difference between revisions of "Carboplatin (Paraplatin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 28: | Line 28: | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Low-grade glioma]] | *[[Low-grade glioma]] | ||
| + | *[[Mantle cell lymphoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
*[[Mesothelioma]] | *[[Mesothelioma]] | ||
| Line 130: | Line 131: | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Low-grade glioma medications]] | [[Category:Low-grade glioma medications]] | ||
| + | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Mesothelioma medications]] | [[Category:Mesothelioma medications]] | ||
Revision as of 02:12, 23 August 2018
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Dosing information
Calvert formula
- Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. link to original article contains verified formula PubMed
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Bladder cancer
- Breast cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Ewing's sarcoma
- Extranodal NK/T-cell lymphoma, nasal type
- Gastric cancer
- Glioblastoma
- Head and neck cancer
- Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
- Melanoma
- Mesothelioma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Prostate cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Uterine cancer
- Unknown primary
Patient drug information
- Carboplatin (Paraplatin) patient drug information (Chemocare)[4]
- Carboplatin (Paraplatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 3/3/1989: Initial FDA approval
Also known as
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Biocarb | Biocarbo | Bioplatinex | Biovinate | Blastocarb | Bonaplatin | Boplatex | Carbo |
| Carbokem | Carbomedac | Carbomerck | Carboplat | Carboplatine | Carboplatino | Carboplatinum | Carbosin |
| Carbotanil | Carbotec | Carbotinol | Careptin | Carplan | Carplanil | Carpsol | Crobextin |
| Cycloplatin | Cycloplatinum | Emorzim | Erbakar | Ercar | Fauldcarbo | Ifacap | Kemocarb |
| Megaplatin | Nealorin | Neocarb | Neocarbo | Oncocarb | Paraplatine | Pharmaplatin | Platamine CS |
| Platinwas | Ribocarbo | Tecnocarb | Vancel | CBDCA | |||
References
Categories:
- Drugs
- Intravenous medications
- Platinum agents
- Alkylating agents
- Irritant chemotherapy
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Bladder cancer medications
- Breast cancer medications
- Cancer of unknown primary medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Ewing's sarcoma medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Gastric cancer medications
- Glioblastoma medications
- Head and neck cancer medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Prostate cancer medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Uterine cancer medications
- FDA approved in 1989
- WHO Essential Cancer Medicine